Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Subscribe To Our Newsletter & Stay Updated
